As drug prices continue to climb and novel therapies challenge traditional pricing models, there is increased momentum behind value-based care and value-based reimbursement.
In this rapidly-evolving climate, value assessments have become an essential component to the successful introduction of any new or innovative treatment. But what are they key drivers of this conversation?
Adapted from his popular webinar, Precision Xtract scientific advisor and Harvard professor Dr. Anupam Jena explores how the definition of value goes beyond quality and cost of care to include other important dimensions that should be factored into developing accurate value frameworks.
This new white paper will help you:
Understand drivers of value-based reimbursement
Address affordability issues
Redefine how value is measured for new technologies